Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Phase 1 results demonstrate that SUL-238, a first-in-class, orally administered, mitochondria-directed drug candidate, is ...

A new study reveals that fragmented sleep causes cellular damage to the brain's blood vessels, providing further evidence to ...

Among 24 such systems (called devices in FDA parlance) authorized since 2015, FDA summaries for 14 lacked data on the ...

Supplemental Nutrition Assistance Program (SNAP) benefits may slow cognitive decline in older adults, highlighting the ...

The prospective cohort study, published in The Journal of Nutrition, found that consuming one or more eggs per week was ...

Adults who participated in the Supplemental Nutrition Assistance Program, or SNAP, experienced slightly slower cognitive ...

Brain experts already know that a number of habits can keep the brain in good shape. Exercise, a healthy diet, staying ...

Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...

Amyloids, the sticky proteins linked to Alzheimer’s disease, may have a surprising role outside the human brain. According to ...

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

This Research Topic aims to explore how cellular metabolites (intermediates or end-products of metabolic processes) influence neuronal activity in both ...